Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Raltegravir

An HIV antiretroviral, the first integrase inhibitor to be approved, in 2007: it stops the virus from inserting its genetic material into the DNA of human cells. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?The suffix '-tegravir', now shared by elvitegravir, dolutegravir, bictegravir and cabotegravir, marks the integrase inhibitors, after the enzyme that 'pastes' viral DNA into the cell's own.

RaltegravirGo to the active ingredient →
RaltegravirActive ingredientRaltegravirCat. No. P-R007-001CAS 518048-05-0
Raltegravir-D3Isotopically labelledRaltegravir-D3Cat. No. P-R007-010CAS 1100750-83-1
Raltegravir-d4Isotopically labelledRaltegravir-d4Cat. No. P-R007-012CAS 2712343-38-7

EDQM standards 3

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.